Drug Profile
Recombinant erythropoietin biosimilar - Opus Bio
Alternative Names: Erythropoietin biosimilar - Opus Bio; LG 747Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Lentigen Technology
- Developer Opus Bio
- Class Antianaemics; Polyethylene glycols; Recombinant erythropoietins; Recombinant fusion proteins
- Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Anaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Anaemia in USA